Pharma in Brief

APRIL 25, 2021

As previously reported , the Proposed FDR Amendments were intended to clarify the regulatory requirements under the Abbreviated New Drug Submission (“ ANDS ”) pathway for generic drug products that contain different forms (e.g.,

Regulation 98

Regulation Medicine Generic Drugs Containment 98

Pharma in Brief

AUGUST 9, 2021

Rolling submissions, which are currently in use for COVID-19 drugs, would be extended to other drugs, such as those which address significant new and emerging infectious diseases in Canada, or which treat, prevent, or diagnose serious or severely debilitating diseases or conditions. Biologic Drugs.

Regulation 98

Regulation Drugs Manufacturing Production 98

Pharma in Brief

JANUARY 9, 2022

In 2020, the FC struck down the new price calculation contained in the amendments but upheld the other impugned amendments. The proposed amendments contain fee changes including the introduction of an excess claim fee for applications with over 20 claims.

Regulation 52

Regulation Manufacturing Medicine Drugs 52

The Pharma Data

JANUARY 17, 2021

As a bioscience accelerator at the leading-edge of the life science industry, XPhyto will target growth through commercialization of existing products and focused investment in impact driven innovation with the potential for extreme value creation. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp. Forward looking statements.

Production 40

Production Drug Delivery Development Drugs 40

Delveinsight

FEBRUARY 5, 2021

Some of these approved products contain nicotine as an active ingredient, while others do not. Moreover, the generic drugs of Zyban are also approved, while for Chantix, its patent is soon going to expire in 2021 in the EU and in 2022 in Japan. Generics in the Market.

Marketing 52

Marketing FDA Approval Branding Production 52

XTalks

AUGUST 2, 2023

Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. It contains the antiviral medications nirmatrelvir and ritonavir. In 2022, Biktarvy generated $10.39 In 2022, Xgeva generated $2.01 Together, these two medications generated a total of €1.70

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

JUNE 16, 2023

There are currently no shortages of cancer drugs in Europe or other countries; however, last year, Germany was experiencing a critical shortage of the breast cancer drug tamoxifen. Medicines for Europe said the supply issues were evidence of the damaging effects of European cost-containment measures.

Drugs 98

Drugs Manufacturing Clinical Supply Chain Clinical Trials 98